Home ›
Entities
› academia
› Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib
Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib
Research article (Journal of Pharmaceutical and Biomedical Analysis, 2023) · cited 15× · AI/ML
Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib
Summary
Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib is a scholarly article[1].
Key Facts
Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib. Retrieved May 24, 2026, from https://4ort.xyz/entity/clinical-validation-and-assessment-of-feasibility-of-volumetric-absorptive-microsampling-vams-for-monitoring-of-nilotini
MLA“Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/clinical-validation-and-assessment-of-feasibility-of-volumetric-absorptive-microsampling-vams-for-monitoring-of-nilotini.
BibTeX@misc{4ortxyz_clinical-validation-and-assessment-of-feasibility-of-volumetric-absorptive-microsampling-vams-for-monitoring-of-nilotini_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib}}, year = {2026}, url = {https://4ort.xyz/entity/clinical-validation-and-assessment-of-feasibility-of-volumetric-absorptive-microsampling-vams-for-monitoring-of-nilotini}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib — https://4ort.xyz/entity/clinical-validation-and-assessment-of-feasibility-of-volumetric-absorptive-microsampling-vams-for-monitoring-of-nilotini (retrieved 2026-05-24)
